Ablynx nets $214mm in Nasdaq IPO
Euronext Brussels-traded Ablynx NV (therapeutic protein platform known as Nanobodies) netted $214mm through an initial public offering on the Nasdaq exchange of 13.1mm ordinary shares (including the overallotment) in the form of American Depositary Shares (ADSs) with each ADS representing the right to receive one ordinary share at $17.50 apiece. The company originally planned to offer 9.2mm ADSs at a price between $17.90-19.08 per ADS.
- Drug Delivery
- Large Molecule
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com